Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma.

Krepler C, Sproesser K, Brafford P, Beqiri M, Garman B, Xiao M, Shannan B, Watters A, Perego M, Zhang G, Vultur A, Yin X, Liu Q, Anastopoulos IN, Wubbenhorst B, Wilson MA, Xu W, Karakousis G, Feldman M, Xu X, Amaravadi R, Gangadhar TC, Elder DE, Haydu LE, Wargo JA, Davies MA, Lu Y, Mills GB, Frederick DT, Barzily-Rokni M, Flaherty KT, Hoon DS, Guarino M, Bennett JJ, Ryan RW, Petrelli NJ, Shields CL, Terai M, Sato T, Aplin AE, Roesch A, Darr D, Angus S, Kumar R, Halilovic E, Caponigro G, Jeay S, Wuerthner J, Walter A, Ocker M, Boxer MB, Schuchter L, Nathanson KL, Herlyn M.

Cell Rep. 2017 Nov 14;21(7):1953-1967. doi: 10.1016/j.celrep.2017.10.021.

2.

Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human ALK mutant neuroblastoma cell lines and xenograft models.

Wang HQ, Halilovic E, Li X, Liang J, Cao Y, Rakiec DP, Ruddy DA, Jeay S, Wuerthner JU, Timple N, Kasibhatla S, Li N, Williams JA, Sellers WR, Huang A, Li F.

Elife. 2017 Apr 20;6. pii: e17137. doi: 10.7554/eLife.17137.

3.

Presence and resistance of Streptococcus agalactiae in vaginal specimens of pregnant and adult non-pregnant women and association with other aerobic bacteria.

Numanović F, Smajlović J, Gegić M, Delibegović Z, Bektaš S, Halilović E, Nurkić J.

Med Glas (Zenica). 2017 Feb 1;14(1):98-105. doi: 10.17392/876-16.

4.

The HDM2 (MDM2) Inhibitor NVP-CGM097 Inhibits Tumor Cell Proliferation and Shows Additive Effects with 5-Fluorouracil on the p53-p21-Rb-E2F1 Cascade in the p53wild type Neuroendocrine Tumor Cell Line GOT1.

Reuther C, Heinzle V, Nölting S, Herterich S, Hahner S, Halilovic E, Jeay S, Wuerthner JU, Aristizabal Prada ET, Spöttl G, Maurer J, Auernhammer CJ.

Neuroendocrinology. 2018;106(1):1-19. doi: 10.1159/000453369. Epub 2016 Nov 21.

PMID:
27871087
5.

Correction: A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097.

Jeay S, Gaulis S, Ferretti S, Bitter H, Ito M, Valat T, Murakami M, Ruetz S, Guthy DA, Rynn C, Jensen MR, Wiesmann M, Kallen J, Furet P, Gessier F, Holzer P, Masuya K, Würthner J, Halilovic E, Hofmann F, Sellers WR, Graus Porta D.

Elife. 2016 Nov 17;5. pii: e19317. doi: 10.7554/eLife.19317. No abstract available.

6.

High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells.

Horn T, Ferretti S, Ebel N, Tam A, Ho S, Harbinski F, Farsidjani A, Zubrowski M, Sellers WR, Schlegel R, Porter D, Morris E, Wuerthner J, Jeay S, Greshock J, Halilovic E, Garraway LA, Caponigro G, Lehár J.

Cancer Res. 2016 Dec 1;76(23):6950-6963. Epub 2016 Sep 22.

7.

Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma.

Carita G, Frisch-Dit-Leitz E, Dahmani A, Raymondie C, Cassoux N, Piperno-Neumann S, Némati F, Laurent C, De Koning L, Halilovic E, Jeay S, Wylie A, Emery C, Roman-Roman S, Schoumacher M, Decaudin D.

Oncotarget. 2016 Jun 7;7(23):33542-56. doi: 10.18632/oncotarget.9552.

8.

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, Andreeff M, Armand P, Ballen KK, Barzaghi-Rinaudo P, Cahill S, Clark RA, Cooke VG, Davids MS, DeAngelo DJ, Dorfman DM, Eaton H, Ebert BL, Etchin J, Firestone B, Fisher DC, Freedman AS, Galinsky IA, Gao H, Garcia JS, Garnache-Ottou F, Graubert TA, Gutierrez A, Halilovic E, Harris MH, Herbert ZT, Horwitz SM, Inghirami G, Intlekofer AM, Ito M, Izraeli S, Jacobsen ED, Jacobson CA, Jeay S, Jeremias I, Kelliher MA, Koch R, Konopleva M, Kopp N, Kornblau SM, Kung AL, Kupper TS, LeBoeuf NR, LaCasce AS, Lees E, Li LS, Look AT, Murakami M, Muschen M, Neuberg D, Ng SY, Odejide OO, Orkin SH, Paquette RR, Place AE, Roderick JE, Ryan JA, Sallan SE, Shoji B, Silverman LB, Soiffer RJ, Steensma DP, Stegmaier K, Stone RM, Tamburini J, Thorner AR, van Hummelen P, Wadleigh M, Wiesmann M, Weng AP, Wuerthner JU, Williams DA, Wollison BM, Lane AA, Letai A, Bertagnolli MM, Ritz J, Brown M, Long H, Aster JC, Shipp MA, Griffin JD, Weinstock DM.

Cancer Cell. 2016 Jul 11;30(1):183. doi: 10.1016/j.ccell.2016.06.008. Epub 2016 Jul 11. No abstract available.

9.

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, Andreeff M, Armand P, Ballen KK, Barzaghi-Rinaudo P, Cahill S, Clark RA, Cooke VG, Davids MS, DeAngelo DJ, Dorfman DM, Eaton H, Ebert BL, Etchin J, Firestone B, Fisher DC, Freedman AS, Galinsky IA, Gao H, Garcia JS, Garnache-Ottou F, Graubert TA, Gutierrez A, Halilovic E, Harris MH, Herbert ZT, Horwitz SM, Inghirami G, Intlekofer AM, Ito M, Izraeli S, Jacobsen ED, Jacobson CA, Jeay S, Jeremias I, Kelliher MA, Koch R, Konopleva M, Kopp N, Kornblau SM, Kung AL, Kupper TS, LeBoeuf NR, LaCasce AS, Lees E, Li LS, Look AT, Murakami M, Muschen M, Neuberg D, Ng SY, Odejide OO, Orkin SH, Paquette RR, Place AE, Roderick JE, Ryan JA, Sallan SE, Shoji B, Silverman LB, Soiffer RJ, Steensma DP, Stegmaier K, Stone RM, Tamburini J, Thorner AR, van Hummelen P, Wadleigh M, Wiesmann M, Weng AP, Wuerthner JU, Williams DA, Wollison BM, Lane AA, Letai A, Bertagnolli MM, Ritz J, Brown M, Long H, Aster JC, Shipp MA, Griffin JD, Weinstock DM.

Cancer Cell. 2016 Apr 11;29(4):574-586. doi: 10.1016/j.ccell.2016.03.008. Erratum in: Cancer Cell. 2016 Jul 11;30(1):183.

10.

Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097.

Weisberg E, Halilovic E, Cooke VG, Nonami A, Ren T, Sanda T, Simkin I, Yuan J, Antonakos B, Barys L, Ito M, Stone R, Galinsky I, Cowens K, Nelson E, Sattler M, Jeay S, Wuerthner JU, McDonough SM, Wiesmann M, Griffin JD.

Mol Cancer Ther. 2015 Oct;14(10):2249-59. doi: 10.1158/1535-7163.MCT-15-0429. Epub 2015 Jul 23.

11.

A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097.

Jeay S, Gaulis S, Ferretti S, Bitter H, Ito M, Valat T, Murakami M, Ruetz S, Guthy DA, Rynn C, Jensen MR, Wiesmann M, Kallen J, Furet P, Gessier F, Holzer P, Masuya K, Würthner J, Halilovic E, Hofmann F, Sellers WR, Graus Porta D.

Elife. 2015 May 12;4. pii: e06498. doi: 10.7554/eLife.06498. Erratum in: Elife. 2016 Nov 17;5:null.

12.

Analysis of the influence of type of diabetes mellitus on the development and type of glaucoma.

Halilovic EA, Ljaljevic S, Alimanovic I, Mavija M, Oros A, Nisic F.

Med Arch. 2015 Feb;69(1):34-7. doi: 10.5455/medarh.2015.69.34-37. Epub 2015 Feb 21.

13.

Optic neuritis as first clinical manifestations the multiple sclerosis.

Halilovic EA, Alimanovic I, Suljic E, Hassan NA.

Mater Sociomed. 2014 Aug;26(4):246-8. doi: 10.5455/msm.2014.246-2481. Epub 2014 Aug 26.

14.

Relation between near work and myopia progression in student population.

Muhamedagic L, Muhamedagic B, Halilovic EA, Halimic JA, Stankovic A, Muracevic B.

Mater Sociomed. 2014 Apr;26(2):100-3. doi: 10.5455/msm.2014.26.100-103. Epub 2014 Apr 11.

15.

Influence of the optic disc size on cup diameter in patients with glaucoma simplex chronicum.

Dervisevic E, Halilovic EA, Masic T, Dervisevic A.

Med Arch. 2013;67(4):272-4.

PMID:
24520752
16.

Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas.

Lito P, Pratilas CA, Joseph EW, Tadi M, Halilovic E, Zubrowski M, Huang A, Wong WL, Callahan MK, Merghoub T, Wolchok JD, de Stanchina E, Chandarlapaty S, Poulikakos PI, Fagin JA, Rosen N.

Cancer Cell. 2012 Nov 13;22(5):668-82. doi: 10.1016/j.ccr.2012.10.009.

17.

PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.

Halilovic E, She QB, Ye Q, Pagliarini R, Sellers WR, Solit DB, Rosen N.

Cancer Res. 2010 Sep 1;70(17):6804-14. doi: 10.1158/0008-5472.CAN-10-0409. Epub 2010 Aug 10.

18.

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.

Joseph EW, Pratilas CA, Poulikakos PI, Tadi M, Wang W, Taylor BS, Halilovic E, Persaud Y, Xing F, Viale A, Tsai J, Chapman PB, Bollag G, Solit DB, Rosen N.

Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14903-8. doi: 10.1073/pnas.1008990107. Epub 2010 Jul 28.

19.

4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors.

She QB, Halilovic E, Ye Q, Zhen W, Shirasawa S, Sasazuki T, Solit DB, Rosen N.

Cancer Cell. 2010 Jul 13;18(1):39-51. doi: 10.1016/j.ccr.2010.05.023.

20.

Genomic and biological characterization of exon 4 KRAS mutations in human cancer.

Janakiraman M, Vakiani E, Zeng Z, Pratilas CA, Taylor BS, Chitale D, Halilovic E, Wilson M, Huberman K, Ricarte Filho JC, Persaud Y, Levine DA, Fagin JA, Jhanwar SC, Mariadason JM, Lash A, Ladanyi M, Saltz LB, Heguy A, Paty PB, Solit DB.

Cancer Res. 2010 Jul 15;70(14):5901-11. doi: 10.1158/0008-5472.CAN-10-0192. Epub 2010 Jun 22.

21.

Homocysteine in angiographically proven coronary disease.

Halilovic E, Kabil E, Halilovic E.

Med Arh. 2009;63(5):252-6.

PMID:
20380122
22.

Genetic predictors of MEK dependence in non-small cell lung cancer.

Pratilas CA, Hanrahan AJ, Halilovic E, Persaud Y, Soh J, Chitale D, Shigematsu H, Yamamoto H, Sawai A, Janakiraman M, Taylor BS, Pao W, Toyooka S, Ladanyi M, Gazdar A, Rosen N, Solit DB.

Cancer Res. 2008 Nov 15;68(22):9375-83. doi: 10.1158/0008-5472.CAN-08-2223.

23.

Therapeutic strategies for inhibiting oncogenic BRAF signaling.

Halilovic E, Solit DB.

Curr Opin Pharmacol. 2008 Aug;8(4):419-26. doi: 10.1016/j.coph.2008.06.014. Epub 2008 Aug 3. Review.

PMID:
18644254
24.

[Congenital optic disc excavatio].

Halilović EA, Ibisević M.

Med Arh. 2007;61(4):260-1. Bosnian.

PMID:
18298005
25.

[Low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol in coronary artery disease].

Halilović E, Kabil E, Ljuca F, Nuhbegović S, Berbić S, Halilović E.

Med Arh. 2007;61(2 Suppl 1):7-10. Bosnian.

PMID:
21553440
26.

[Coronary disease and left branch block].

Merić M, Halilović E, Baraković F, Kabil E.

Med Arh. 2004;58(5):288-91. Bosnian.

PMID:
15628253
27.

[Clinical aspects and haemodynamic parameters for monitoring patients with acute myocardial infarct (AIM)].

Halilović E, Merić M, Terzić I, Halilović E.

Med Arh. 2004;58(4):223-6. Bosnian.

PMID:
15526590
28.

Mycoplasma infection induces a scleroderma-like centrosome autoantibody response in mice.

Gavanescu I, Pihan G, Halilovic E, Szomolanyi-Tsuda E, Welsh RM, Doxsey S.

Clin Exp Immunol. 2004 Aug;137(2):288-97.

29.

Centrosomal anchoring of protein kinase C betaII by pericentrin controls microtubule organization, spindle function, and cytokinesis.

Chen D, Purohit A, Halilovic E, Doxsey SJ, Newton AC.

J Biol Chem. 2004 Feb 6;279(6):4829-39. Epub 2003 Nov 1.

30.

[Intracoronary radiotherapy].

Halilović E, Meinertz T, Merić M, Terzić I, Halilović E, Halilović E.

Med Arh. 2003;57(4):255-7. Croatian.

PMID:
14528724
31.

A novel human protein of the maternal centriole is required for the final stages of cytokinesis and entry into S phase.

Gromley A, Jurczyk A, Sillibourne J, Halilovic E, Mogensen M, Groisman I, Blomberg M, Doxsey S.

J Cell Biol. 2003 May 12;161(3):535-45. Epub 2003 May 5.

32.

[Morphologic changes in the interventricular septum and the posterior wall of the left ventricle in patients on hemodialysis].

Nuhbegović S, Halilbasić A, Karamehić J, Halilović E, Merić M.

Med Arh. 2000;54(2):69-70. Croatian.

PMID:
10934830
33.

[Effect of hemodialysis on functional parameters of the left ventricle].

Nuhbegović S, Halilbasić A, Karamehić J, Halilović E, Merić M.

Med Arh. 1999;53(1):19-20. Croatian.

PMID:
10356925
34.

[Electrophysiologic study and endocardial ECG mapping in the detection of causes of heart rhythm disorders].

Halilović E, Meinertz T, Weiss C.

Med Arh. 1998;52(2):61-3. Croatian.

PMID:
9769636
35.

[Nifedipine in acute myocardial infarction (author's transl)].

Oeff M, Beck OA, Halilović E, Hochrein H.

Dtsch Med Wochenschr. 1980 Oct 24;105(43):1497-501. German.

PMID:
7428655

Supplemental Content

Loading ...
Support Center